Sign In
Buy MIRM
$105.95
-6.64 (-5.90%)
At Close: Jul 31, 2026
Bank of New York Mellon Corp Buys New Stake in Mirum Pharmaceuticals (NASDAQ:MIRM)
09:18am, Friday, 01'st May 2020
Bank of New York Mellon Corp bought a new stake in shares of Mirum Pharmaceuticals (NASDAQ:MIRM) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund b
Mirum Appoints Global Blood's Radovich as Its Chief Operating Officer
10:26pm, Tuesday, 28'th Apr 2020
Mirum Pharmaceuticals (NASDAQ: ]) has added Peter Radovich to its C-suite as its chief operating officer. Radovich was most recently executive vice
Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer
08:19pm, Tuesday, 28'th Apr 2020
Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer
Zacks: Brokerages Anticipate Mirum Pharmaceuticals (NASDAQ:MIRM) to Announce -$0.81 Earnings Per Share
10:18am, Friday, 24'th Apr 2020
Wall Street analysts predict that Mirum Pharmaceuticals (NASDAQ:MIRM) will post earnings per share of ($0.81) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have
Athenex (NASDAQ:ATNX) & Mirum Pharmaceuticals (NASDAQ:MIRM) Critical Contrast
06:40am, Thursday, 16'th Apr 2020
Athenex (NASDAQ:ATNX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of thei
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak PTCT;SRPT;IONS;HALO;MIRM;DBVT;SNDX;NERV;XFOR;MLND;CBAY
11:16am, Monday, 23'rd Mar 2020
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak Citi PTCT SRPT IONS HALO MIRM DBVT SNDX NERV XFOR MLND CBAY
Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
08:02pm, Thursday, 12'th Mar 2020
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today reported financial an
Mirum Pharmaceuticals to Participate at Four Upcoming Conferences
09:01pm, Tuesday, 18'th Feb 2020
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, to
Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund
02:00pm, Thursday, 16'th Jan 2020
Frazier Healthcare Partners announced today the closing of Frazier Life Sciences X, L.P., exceeding its target and closing on more than $617 million in capital commitments in an oversubscribed fundrai
Mirum Pharmaceuticals Promotes Ian Clements to Chief Financial Officer
02:00pm, Tuesday, 14'th Jan 2020
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the promoti
Mirum Pharmaceuticals Announces Pricing of Public Offering
01:15am, Thursday, 09'th Jan 2020
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the pricing
Is Mirum Pharmaceuticals, Inc. (MIRM) A Good Stock To Buy?
03:40pm, Tuesday, 24'th Dec 2019
Is Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite inv
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Ama
The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
01:14pm, Friday, 08'th Nov 2019
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL
